Eliza B. Geer, MD joined the faculty at The Mount Sinai Medical Center in July, 2006 with an appointment in the Division of Endocrinology and a secondary appointment in the Department of Neurosurgery. After graduating from Columbia University, she attended Mount SinaiSchool of Medicine, graduating with Distinction in Research. She completed her Internship and Residency in Internal Medicine at Columbia Presbyterian Medical Center, where she became involved in neuroendocrine research, conducting studies on the hypothalamic-pituitary-adrenal axis and acromegaly. After completing her Residency, she conducted a year of clinical research at Columbia's Obesity Research Center, funded by a NIH T32 grant, where she focused on body composition and appetite in acromegaly. She then completed a fellowship in Endocrinology, Diabetes and Bone Disease at the Mount Sinai Medical Center, graduating in 2006.www.mountsinai.org/pituitary
Clinical Research Education Program [CLR]
MD, Mount Sinai School of Medicine
BA, Columbia University
Internship, Internal Medicine
NY Columbia Presbyterian Med. Ctr.
Residency, Internal Medicine
NY Columbia Presbyterian Med. Ctr.
Fellowship, Endocrinology & Metabolism
Mount Sinai Hospital
Dr. Geer's clinical and research interests include pituitary diseases and neuroendocrinology. She is the principal investigator of a number of studies investigating body composition, adipose tissue regulation, appetite, and long term outcomes in patients with Cushing's Disease and other pituitary diseases; these studies are funded by a NIH K23 award. She was awarded the Dr. Harold and Golden Lamport Research Award for Clinical Research in 2012, and the Mount Sinai Endocrinologist of the Year award for outstanding service to the Icahn School of Medicine and Mount Sinai Hospital in 2013.
A randomized double-blind multicenter phase 3 study to evaluate the efficacy and safety of Pasireotide LAR in patients with Cushing's disease
The purpose of this study is to find out if the long acting formulation of Pasireotide LAR (long acting release) is safe and has beneficial effects in people who have hypercortisolism (excess of cortisol) caused by ACTH-dependent Cushing's disease.
An open label study to assess the safety and efficacy of COR-003 (2S 4R-Ketoconazole) in the treatment of Endogenous Cushing's syndrome
The purpose of this clinical research study is to test the effects of this experimental new drug COR-003 on people with Cushing's syndrome by measuring the cortisol levels in the urine and to see if there is any harm caused when using COR-003.
A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease
The purpose of this study is to confirm the effectiveness and safety of LCI699 in treating patients with Cushing's disease.
Adipose Tissue Distribution/ Adipokines in Cushing's Disease
The purpose of this study is to investigate the role of appetite hormones and adipokines in the abnormal body composition seen in Cushing's Disease
Body Composition & Metabolic Syndrome /Cushing's Disease
The purpose of this study is to investigate inflammatory markers, the metabolic syndrome, and body composition in Cushing's Disease
An Acromegaly open-label multi-center Safety monitoring program for treating patients with SOM230 (pasireotide) LAR who have need to receive medical therapy (ACCESS)
The purpose of this study is to find out if the long acting formulation of drug Pasireotide is safe and has beneficial effects in people who have Acromegaly.
Carluccio A, Sundaram NK, Chablani S, Goldberg L, Lambert JK, Post KD, Geer EB. Predictors of quality of life in 102 patients with treated Cushing’s disease. Clin Endocrinol (oxf) 2014 June; 13.
Lambert J, Goldberg L, Fayngold S, Kostadinov J, Post K, Geer EB. Predictors of Mortality and Long-Term Outcomes in Treated Cushing’s disease: A Study of 346 Patients. J Clin Endocrinol Metab 2013 Feb 7;.
Sundaram N, Carluccio A, Geer EB. Characterization of Persistent and Recurrent Cushing’s disease. Pituitary 2013 Aug 29;.
Preface as invited issue editor for Endocrinol Metab Clin North Am. . Elsevier Press 2013 Sep:42(3):xvii-xviii.
Sundaram N, Geer EB, Greenwald B. The Impact of Traumatic Brain Injury on Pituitary Function. Endocrinol Metab Clin North Am 2013 Sep; 42(3):: 565-83.
Goddard G, Geer EB EB. A Case-Based Guide to Clinical Endocrinology: “Adrenal Incidentaloma and Subclinical Hypercortisolism. Springer Clinical Medicine 2013;.
Geer EB, Shen W, Strohmayer E, Post K, Freda P. Body Composition and Cardiovascular Risk Markers after Remission of Cushing’s disease: a Prospective Study using Whole-Body MRI. J Clin Endocrinol Metab 2012 March;.
Messer C, Boston R, LeRoith D, Geer EB, Miller J, Messer M, Futterweit W. Pancreatic Beta-cell Dysfunction in PCOS: the Role of Metformin. Endocr Pract 2012 March;.
Skamagas M, Geer EB. Autoimmune Hyperthyroidism due to Secondary Adrenal Insufficiency: Resolution with Glucocorticoids. Endocr Pract 2011 Jan-Feb;(17(1)): 85-90.
Geer EB, Shen W, Gallagher D, Punyanitya M, Looker H, Post K, Freda P. MRI Assessment of Lean and Adipose Tissue Distribution in Female Patients with Cushing’s disease. Clin Endocrinol (Oxf) 2010 Oct; 73(4): 469-75.
Freda PU, Reyes-Vidal CM, Geer EB, Arias-Mendoza F, Gallagher D, Heymsfield SB. Skeletal Muscle Mass in Acromegaly Assessed by magnetic Resonance Imaging and Dual X-Ray Absorptiometry. J C Endocrinol Metab 2009 August; 94(8): 2880-2886.
Geer EB, Shen W. Gender Differences in Insulin Resistance, Body Compositon, and Energy Balance. Gend Medicine 2009; 6: 60-75.
Freda PU, Shen W, Heymsfield SB, Reyes CM, Geer EB, Bruce JN, Gallagher D. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with GH & IGF-1 excess due to acromegaly. J Clin Endocrinol Metab 2008 Jun; 93(6): 2334-2343.
Geer EB, Landman RE, Wardlaw SL, Conwell IM, Freda PU. Stimulation of the Hypothalamic-Pituitary-Adrenal Axis with the Opioid Antagonist Nalmefene. Pituitary 2005; 8(2): 115-122.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Geer during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.